Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 18,005 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,005 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15. Following the completion of the transaction, the chief financial officer owned 270,046 shares of the company’s stock, valued at $7,515,380.18. This represents a 6.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $31.01 on Tuesday. The business’s 50 day simple moving average is $19.95 and its 200-day simple moving average is $31.92. The firm has a market capitalization of $7.07 billion, a price-to-earnings ratio of 60.80, a price-to-earnings-growth ratio of 2.74 and a beta of 2.32. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Truist Financial restated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $13.25 to $24.00 in a research report on Tuesday, March 10th. Finally, Leerink Partners increased their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $31.86.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quent Capital LLC purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the 3rd quarter valued at about $28,000. Silicon Valley Capital Partners purchased a new position in Hims & Hers Health in the 3rd quarter valued at about $48,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth about $28,000. Finally, Bogart Wealth LLC boosted its stake in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Investor momentum: Traders are buying HIMS on optimism about its peptide drug pipeline and reports of a potential deal with Novo Nordisk, which, coupled with an upcoming May 11 earnings report, is cited as the main catalyst for the rally. Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
• Neutral Sentiment: Biotech sector news: Positive clinical data at peers (e.g., Nektar’s alopecia results) is lifting sentiment across small-cap biopharma stocks; this sector-wide risk-on tone may be contributing to flows into HIMS even if the news isn’t company-specific. This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness.
• Neutral Sentiment: Short-interest update: A recent short-interest note was published; changes in short interest can amplify moves into earnings but the update itself doesn’t clearly favor one direction. Monitor short-interest levels for potential squeeze risk. Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update
• Negative Sentiment: Insider sales: CFO Oluyemi Okupe sold a block of shares on Apr 16–17 (total ~54,927 shares) under a pre‑arranged Rule 10b5‑1 plan — roughly $1.46M at the reported prices — reducing his stake. The sales are disclosed in an SEC Form 4 filing; because they were executed under a 10b5‑1 plan the signal is muted but still a short‑term caution for sentiment. SEC Form 4 – Insider Sale

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.